CA2109796C - Modulation of cellular response to external stimuli - Google Patents

Modulation of cellular response to external stimuli Download PDF

Info

Publication number
CA2109796C
CA2109796C CA002109796A CA2109796A CA2109796C CA 2109796 C CA2109796 C CA 2109796C CA 002109796 A CA002109796 A CA 002109796A CA 2109796 A CA2109796 A CA 2109796A CA 2109796 C CA2109796 C CA 2109796C
Authority
CA
Canada
Prior art keywords
omega
dag
cells
levels
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002109796A
Other languages
English (en)
French (fr)
Other versions
CA2109796A1 (en
Inventor
James A. Bianco
Stuart L. Bursten
Jack W. Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of CA2109796A1 publication Critical patent/CA2109796A1/en
Application granted granted Critical
Publication of CA2109796C publication Critical patent/CA2109796C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002109796A 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli Expired - Lifetime CA2109796C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70499291A 1991-05-24 1991-05-24
US704,992 1991-05-24
US73222791A 1991-07-16 1991-07-16
US732,227 1991-07-16
PCT/US1992/004349 WO1992021344A2 (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli

Publications (2)

Publication Number Publication Date
CA2109796A1 CA2109796A1 (en) 1992-12-10
CA2109796C true CA2109796C (en) 2004-04-27

Family

ID=27107424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002109796A Expired - Lifetime CA2109796C (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli

Country Status (7)

Country Link
EP (2) EP1214938A3 (enExample)
JP (1) JP3566719B2 (enExample)
AU (1) AU664189B2 (enExample)
CA (1) CA2109796C (enExample)
IE (1) IE921683A1 (enExample)
IL (1) IL101982A (enExample)
WO (1) WO1992021344A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2191013T3 (es) * 1992-03-04 2003-09-01 Cell Therapeutics Inc Compuestos de xantina enantiomeros hidroxilados.
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
US5580874A (en) * 1992-03-04 1996-12-03 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
EP0728003A1 (en) * 1993-11-12 1996-08-28 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
AU1831395A (en) * 1994-01-14 1995-08-01 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
CA2166324A1 (en) * 1994-03-08 1995-09-14 Stuart L. Bursten Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer
US5843943A (en) * 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
CA2208580A1 (en) * 1994-12-29 1996-07-11 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
EP1091960A1 (en) * 1998-06-29 2001-04-18 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
JP2011510975A (ja) * 2008-01-31 2011-04-07 韓国科学技術研究院 脳腫瘍の予防用または治療用の組成物
KR20090084150A (ko) * 2008-01-31 2009-08-05 한국과학기술연구원 이노시톨 1,4,5-트리포스페이트 수용체 서브타입 3 억제용조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
GB8621869D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Treatment
IL106861A (en) * 1986-12-31 1997-02-18 Hoechst Roussel Pharma Pentoxifylline metabolites and pharmaceutical formulations containing them for inhibiting the activity of interleukin-1 and leukocyte-derived cytokines
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions
EP0490181A1 (en) * 1990-11-30 1992-06-17 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for preparation of a medicament having immunosuppressing activity
EP0493682A3 (en) * 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
ATE142498T1 (de) * 1991-05-23 1996-09-15 Hoechst Ag Die verwendung von 1-(5-oxohexyl)-3-methyl-7-n- propyl-xanthin in der gefässchirurgie

Also Published As

Publication number Publication date
EP1214938A3 (en) 2003-08-06
JPH07500085A (ja) 1995-01-05
WO1992021344A3 (en) 1993-12-09
CA2109796A1 (en) 1992-12-10
IL101982A0 (en) 1992-12-30
AU664189B2 (en) 1995-11-09
JP3566719B2 (ja) 2004-09-15
IE921683A1 (en) 1992-12-02
EP0573617A4 (enExample) 1994-02-09
WO1992021344A2 (en) 1992-12-10
IL101982A (en) 2000-02-29
EP0573617A1 (en) 1993-12-15
AU2247592A (en) 1993-01-08
EP1214938A2 (en) 2002-06-19

Similar Documents

Publication Publication Date Title
US5856115A (en) Assay for identification therapeutic agents
CA2109796C (en) Modulation of cellular response to external stimuli
Cho-Chung Site-Selective 8-Chloro-Cyclic Adenosine 3', 5'-Monophosphate as
EP1778224B1 (en) Flt3 inhibitors for immune suppression
US5440041A (en) Acetal or ketal substituted xanthine compounds
US5340813A (en) Substituted aminoalkyl xanthine compounds
JP2004002467A (ja) 鏡像異性体ヒドロキシル化キサンチン化合物
KR20200105731A (ko) 포르볼 에스테르의 조성물
Liu et al. Inhibitory effect of baicalein on IL‐6‐mediated signaling cascades in human myeloma cells
US20170348369A1 (en) Plant Extract and Its Therapeutic Use
EP3043809B1 (en) Filipendula vulgaris extract and uses thereof
JP4167733B2 (ja) ＮＦ−κＢ活性化抑制剤
AU2014272656A1 (en) Extract of Cynara ssp. and uses thereof
AU2015352042B2 (en) Titled extracts of Cynara scolymus for use in the treatment of mesothelioma
US5795897A (en) Oxohexyl methylxanthine compounds
Asano et al. Inhibition of murine chronic graft-versus-host disease by the chloroform extract of Tripterygium wilfordii Hook f
US20160303080A1 (en) Compositions and methods for treating hematological malignancies
JPWO1998055493A1 (ja) 天然型抗腫瘍性又は抗ウイルス性物質およびその用途
KR100191901B1 (ko) 새로운 세스퀴테르펜 에스테르 화합물
US20220079915A1 (en) Immunosuppressive pharmaceutical composition and application thereof
CN114191430A (zh) 青蒿素在靶向抑制髓系来源的抑制性细胞及其在制备肿瘤免疫治疗药物中的应用
Zhu et al. Thalidomide prolongs experimental autoimmune neuritis in Lewis rats
Anathy et al. Activation of Pyruvate Kinase M2 attenuates expression of pro-inflammatory mediators in house dust mite-induced allergic airways disease
HK40120251A (en) Nkt cell ligand-containing liposome composition
US6472385B1 (en) Compositions and methods to enhance cancer chemotherapy in p53 defective tumors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121202